Previous 10 | Next 10 |
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Clinical-stage biotech, Aligos Therapeutics (NASDAQ:ALGS) announced on Tuesday that the company decided to discontinue the development of its chronic hepatitis B (CHB) candidate, ALG-020572 after a trial subject experienced a serious adverse event (SAE). Dosing of the first cohort of the tria...
Dosing in the first cohort discontinued after multiple reports of ALT flares suggestive of drug-induced liver toxicity Funds will be redirected to support ongoing clinical programs, including ALG-000184 (Class-II CAM for CHB) and ALG-055009 (THR- agonist for NASH), and to accele...
Aligos Therapeutics press release (NASDAQ:ALGS): Q4 GAAP EPS of -$0.89 misses by $0.06. Q4 Cash , cash equivalents $205.8M For further details see: Aligos Therapeutics GAAP EPS of -$0.89 misses by $0.06
CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1b ASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1 st cohort fully enrolled siRNA (ALG-125755) progressing on track through Phase 1 enabling no...
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the c...
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph...
Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete First chronic hepatitis B patient dosed in initial cohort, each of which will be administered 7 subcutaneous doses over 29 days SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEW...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Aligos Therapeutics, Inc. (“Aligos” or the “Company”) (NASDAQ: ALGS) on behalf of Aligos stockholders. Our investigation concerns w...
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has expanded i...
News, Short Squeeze, Breakout and More Instantly...
Aligos Therapeutics Inc. Company Name:
ALGS Stock Symbol:
NASDAQ Market:
Aligos Therapeutics Inc. Website:
Key Opinion Leader (KOL) event with Dr. Mark Sulkowski to discuss his perspectives on the chronic suppression regulatory pathway and future development plans following positive feedback from the FDA to move forward with chronic HBV DNA suppression as the primary efficacy endpoint Schedu...
2024-07-09 10:10:00 ET July 9, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Tech, Biotech, Cleantech and Mining Sectors. The newest tech company is involved in AI and Blo...
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive...